ROBOCOP (ROBOtic Care of Poststroke Pain): Study Protocol for a Randomized Trial to Assess Robot-Assisted Functional and Motor Recovery and Impact on Poststroke Pain Development

Loris Pignolo 1, Paolo Tonin 1, Pierluigi Nicotera 2, Giacinto Bagetta 3 and Damiana Scuteri 1,3*

1 Regional Center for Serious Brain Injuries, S. Anna Institute, Crotone, Italy; 2 German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; 3 Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy

Background: Stroke is one of the most frequent causes of death and disability worldwide. It is accompanied by the impaired motor function of the upper extremities in over 69% of patients up to hemiplegia in the following 5 years in 56% of cases. This condition often is characterized by chronic poststroke pain, difficult to manage, further worsening quality of life. Poststroke pain occurs within 3–6 months. Robot-assisted neurorehabilitation using the Automatic Recovery Arm Motility Integrated System (ARAMIS) has proven efficacy in motor function recovery exploiting the movements and the strength of the unaffected arm. The rationale of the ROBOCOP (ROBOtic Care of Poststroke pain) randomized trial is the assessment of the impact of robot-assisted functional and motor recovery on the prevention of poststroke pain.

Methods: A total of 118 patients with hemiplegic arms due to stroke will be enrolled and randomly allocated with a 1:1 ratio to ARAMIS or conventional neurorehabilitation group. After a baseline screening at hospital discharge, ARAMIS or conventional rehabilitation will be performed for 8 weeks. The primary endpoint is the prevention of the development of poststroke pain and the secondary endpoints are prevention of spasticity and efficacy in clinical motor rehabilitation. The primary outcome measures consist in the visual analog scale and the doleur neuropathique 4 and the secondary outcome measures include: the Modified Ashworth Scale, the Resistance to Passive movement Scale; the Upper Extremity Subscale of the Fugl–Meyer Motor Assessment; the Action Research Arm Test; the Barthel Index for activities of daily living; and the magnetic resonance imaging (MRI) recovery-related parameters. After baseline, both primary and secondary outcome measures will be performed in the following time points: 1 month after stroke ($t_1$, half of the rehabilitation); 2 months after stroke ($t_2$, after rehabilitation); and 3 months ($t_3$) and 6 months ($t_4$) after stroke, critical for poststroke pain development.
INTRODUCTION

Background and Rationale

Stoke represents one of the most serious causes of death and disability-adjusted life-years lost (1) destined to keep increasing due to global aging. One of the most common long-term disabilities occurring in over 69% of cerebrovascular lesions consists of impaired motor function of the upper extremities up to hemiplegia in the following 5 years in 56% of cases (2, 3). Stroke is complicated by the occurrence of poststroke pain usually within 6 months from the acute event (4), with poststroke pain syndromes reported in up to 30%−40% of stroke outliving patients (5), chronic in 11−55% of patients (6). The latter include pain caused by different pathophysiology in which nociceptive and neuropathic features can coexist ranging from pain secondary to spasticity, shoulder pain, complex regional pain syndrome (CRPS), and headache, in 1 out of 10 stroke sufferers, that is, migraine-like in 31.3% cases (7), to central poststroke pain (8). Shoulder pain is the most frequent affecting some 30−40% of stroke survivors (6). Lenticulocapsular strokes can cause hemiparesis with consequent shoulder pain (9). The development of poststroke pain correlates to the severity of stroke and paresis is associated with a 3.1-fold higher risk for stroke-related pain (10). Unfortunately, often patients suffering from pain after stroke do not find relief in current analgesic treatment guidelines are lacking (because it is not supported by clinical trials, as a consequence, studies have not been designed specifically for this condition, thus poststroke pain, the number of patients is very small and these latter include pain caused by different pathophysiology in which nociceptive and neuropathic features can coexist ranging from pain secondary to spasticity, shoulder pain, complex regional pain syndrome (CRPS), and headache, in 1 out of 10 stroke sufferers, that is, migraine-like in 31.3% cases (7), to central poststroke pain (8). Shoulder pain is the most frequent affecting some 30−40% of stroke survivors (6). Lenticulocapsular strokes can cause hemiparesis with consequent shoulder pain (9). The development of poststroke pain correlates to the severity of stroke and paresis is associated with a 3.1-fold higher risk for stroke-related pain (10). Unfortunately, often patients suffering from pain after stroke do not find relief in current analgesic treatment guidelines are lacking (because it is not supported by clinical trials, as a consequence, studies have not been designed specifically for this condition, thus poststroke pain, the number of patients is very small and these studies have not been designed specifically for this condition, thus usually not evaluating the correlation between rehabilitation, pain, and physical functioning after stroke (11). Actually, stroke survivors do not even benefit from clinical trials on the novel preventative treatment of migraine, e.g., the anticalcitonin gene-related peptide monoclonal antibody eptinezumab that can provide rapid and longer-lasting action (12). This is often due to the lack of use of pain scales for an objective pain assessment validated in specific populations, e.g., patients affected by stroke, and this problem becomes even more worrying for patients with aphasia and noncommunicative and in the pandemic emergency (13−16). Robot-assisted neurorehabilitation for patients with stroke having the Integrated Robotic System for Stroke (IRSS) prototype Automatic Recovery Arm Motility Integrated System (ARAMIS) has provided a significant improvement of motor recovery (17). It consists of two computer-controlled, symmetric, and interacting exoskeletons that impress to the paretic arm the same strength and movement of the healthy arm and it has been validated in stroke survivors. The rationale for the use of ARAMIS in poststroke neurorehabilitation of the paretic upper limb relies on the possible prevention of aberrant early plasticity. According to our working hypothesis, ARAMIS might improve plasticity in agreement with the concept underlying the Reinforcement-Induced Movement Therapy (18), avoiding the occurrence of spasticity and hypotonia.

Objectives

In agreement with the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations that support the importance of physical functioning as the core outcome for pain (19) this randomized controlled clinical trial (Calabria Region Ethics Committee protocol N.244 of 09/21/2021) will be the pilot forming the rational basis for the assessment of the efficacy in the use of ARAMIS to prevent chronic poststroke pain development. In fact, according to our working hypothesis, proprioceptive inputs with high-intensive bilateral movement training of the hemiplegic arm can prevent chronic poststroke pain development within the 3−6 months following stroke.

Trial Design

This randomized single-center trial will recruit subacute hemiplegic patients of any age with hemiparesis of the arm after stroke. The trial is designed as a prospective, exploratory, and interventional study without drugs. The study does not request the use of drugs. This study protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist (20).

METHODS

This trial has been approved by the Calabria Region Ethics Committee (protocol N.244 of 09/21/2021) and the ClinicalTrials.gov ID has been requested. According to the D.lgs 196/2003, the Helsinki agreements and subsequent amendments, the Good Clinical Practice and current legislation, the Guidelines for the treatment of personal data in clinical trials of 24 July 2008, and in accordance with European data protection legislation, each participant or his/her legal representative will be required to sign a consent form as acceptance of all aspects of the study contained in the patient information sheet and as a consequent expression of his willingness to participate in the study. The information sheet will be duly illustrated to the subjects or legal representatives by the study staff and the same staff will ensure that the consent form is properly signed and dated by all the parties involved before any procedure foreseen by the protocol is carried out.

Discussion: This is the first clinical trial investigating the efficacy of robot-assisted neurorehabilitation using ARAMIS on poststroke pain prevention. This study could remarkably improve the quality of life of stroke survivors.

Keywords: robot-assisted neurorehabilitation, ARAMIS, stroke recovery, motor rehabilitation, post-stroke pain
Study Setting
The study will be carried out at the Sant’ Anna Institute of Crotone (Calabria, Italy), which is specialized in motor and cognitive treatment and rehabilitation of neurological diseases.

Eligibility Criteria
Consecutive patients, admitted to Sant’ Anna Institute with the diagnosis of stroke after hospital discharge will be enrolled, accordingly with the following inclusion criteria:
- First-ever stroke within 24–72 h from diagnosis confirmed through functional MRI scan, regardless of the side, location, and extension of the lesion;
- Stroke-related hemiplegic patients of any age at hospital discharge within 48–72 h after stroke with fMRI scan of the area affected;
- Severe upper limb impairment, according to the Upper Extremity Subscale of the Fugl–Meyer Motor Assessment [FMA-UE (0-35) (21)];
- Absence of hemiplegic upper limb-related baseline pain based on the visual analog scale (VAS), the bedside active examination with a numerical rating and, also, the douleur neuropathique en 4 questions (DN4) for the evaluation of neuropathic prestroke pain.

Exclusion criteria will be:
- Bilateral impairment;
- Presence of aphasia;
- Presence of cognitive impairment, as assessed using the cognitive assessment scale for patients with stroke (22), to avoid interference of aphasia or hemispatial neglect that may occur with the commonly used Mini-Mental State Examination (23) and Montreal Cognitive Assessment (24);
- Stroke diagnosis without the occurrence of hemiparesis of the upper limb;
- Previous rehabilitation.

Due to the lack of specific observational tools for poststroke pain in noncommunicative patients, this pilot study will not include patients affected by aphasia and cognitive impairment. The informed consent will be obtained by healthcare operators and patients will be informed about the study and they will be provided with a consent form. No additional consent provisions for biological specimens will be needed since the latter will not be collected.

Description of the Intervention
ARAMIS is composed of two computer-controlled, symmetric, and interacting exoskeletons able to compensate for the inadequate strength and accuracy of residual motor function of the paretic arm movements (25) (Figure 1). Through motion capture of the movements of the unaffected arm, the patient can replicate the movements of the healthy arm with the paretic arm in a synchronous, asynchronous, or active-assisted manner (25). Patients in the intervention group will receive only robot-aided and not conventional rehabilitation for a 60 min-session.

The robot-assisted neurorehabilitation using ARAMIS and the conventional rehabilitation consists of 60-min sessions every day for 8 weeks (17, 25). In particular, in the first section of neurorehabilitation (1–4 weeks), all the subjects will be subjected to perform a series of asynchronous exercises according to which the paretic limb repeats each exercise 20 times for a total of 200 repetitions per session. During synchronous exercises, the exoskeleton hosting the paretic limb allows the replication of the sample movements of the parallel exoskeleton hosting the unaffected arm in real time. In the asynchronous exercises, the sample movements have been generated previously by the unaffected arm of the patient or by the arm of the therapist. The basic exercises consist in forearm pronation-supination, elbow flexion-extension, shoulder elevation (30°, 60°, and 90°) and abduction-adduction (30°, 60°, and 80°), and circle movement on the frontal axis of the shoulder and its flexion-extension. On the other side, the functional exercise includes: shoulder elevation 90° + forearm pronation-supination and elbow flexion-extension and the contrary (elbow flexion-extension + forearm pronation-supination); shoulder elevation 90° + two elbow intermediate flexion-extension + forearm intermediate pronation-supination. In the following section (5–8 weeks), the asynchronous exercises are reduced to 100 per session and the number of synchronous exercises is increased to keep constant the total number (200/session). The control group will receive conventional rehabilitation. The latter consists of passive mobilization, neuromotor facilitation of shoulder, arm, forearm, and hand muscles and adoption of postures inhibiting pathological synergies in the first 4 weeks. In the following 4 weeks apart from a passive mobilization, neuromotor facilitation, and posture adopting, also the following exercises will be performed: coordination proximal-distal and of ocular-cephalic movements; "reach to indicate"; hand preconfiguration; "reach, touch, and manipulate"; grasping; exercises for manipulative skills, for the adaptation of the hand to the object without visual feedback and the sensitivity, together with biofeedback and electrostimulation cardiovascular conditioning in the sitting posture, conditioning in the upright posture and exercises for the trunk control.

In case of discontinuation of the treatment, the patient will be excluded from the study. The treatment will be performed by healthcare operators preventing lack of adherence.

Outcomes
The effect of robot-assisted rehabilitation using ARAMIS on the prevention of the development of poststroke pain is the primary endpoint of the ROBOCOP study. The primary outcome measures consist in the assessment of pain through the VAS, including a bedside active examination and probing of somatosensory functions to test touch, temperature, and pain sensations (26). The development of neuropathic components of poststroke pain will be assessed using the DN4. The secondary endpoints include spasticity, tightly linked to pain and developed by up to 40% of patients with hemiparetic stroke, and clinical motor rehabilitation. Spasticity will be assessed using the Modified Ashworth Scale (MAS) (27) and the Resistance to Passive movement Scale (REPAS), based on the Ashworth scale.
Clinical motor rehabilitation will be measured according to the Standardizing Measurement in Arm Rehabilitation Trials [SMART] toolbox of the recommended core set of outcome measures for rehabilitation after stroke (29, 30). The latter includes FMA-UE, the Action Research Arm Test, and the activities of daily living/stroke-specific outcomes of the Barthel Index. The clinical motor rehabilitation will also be characterized through structural and functional MRI scan. In particular, structural MRI is intended to evaluate infarct and injury volume (31) and functional MRI to assess the activation volume in the stroke ipsilateral hemisphere during movement of paretic limb, which is related to the extent of behavioral recovery (32). The connection strength between the ipsilesional primary motor cortex and the contralateral regions will be examined (33).

### Participant Timeline

Patients will be randomly allocated to the intervention or control group in a 1:1 allocation ratio. The enrollment will last up to the achievement of the sample size. The most important time points for the assessment of pain development are 3 and 6 months poststroke, with the addition of measurement time points in the subacute phase (29, 34). In fact, differences in motor activity of paretic limbs 24–36 h after symptoms onset, and also at 3 and 6 months (35, 36) have been demonstrated. Therefore, the assessment of the primary and secondary outcomes will be conducted at the following time points: baseline measurement at Sant’Anna Institute admission (24–72 h since stroke event) ($t_0$); 1 month after stroke ($t_1$), i.e., at half of the rehabilitation period; 2 months after stroke ($t_2$), i.e., after the completion of neurorehabilitation with ARAMIS in the intervention group and...
TABLE 1 | Schedule of enrollment, interventions and assessments according to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT).

| Timepoint         | Study period | Enrolment Allocation | Post-allocation |
|-------------------|--------------|----------------------|-----------------|
|                   | –t₀         | 0                    | t₁   t₂   t₃   t₄ |
| Enrolment         |             |                      |                 |
| Eligibility screen| X           |                      |                 |
| Informed consent  | X           |                      |                 |
| Physical examination| X         |                      |                 |
| Allocation        | X           |                      |                 |
| Interventions     |             |                      |                 |
| ARAMIS            | X X         |                      |                 |
| Conventional neurorehabilitation | X X |                      |                 |
| Assessments       |             |                      |                 |
| Primary endpoint variables | X |                      |                 |
| Secondary endpoint variables | X |                      |                 |
| Assessment of activation volume | X X |                      |                 |
| FAI               | X X         |                      |                 |

of conventional rehabilitation in the nonintervention group; 3 months (t₃) and 6 months (t₄) after stroke, since the latter are critical for rehabilitation and pain development. Routine clinical and neurophysiological assessments will be performed before and at the end of the treatment. Loss of tolerance to the procedure up to discontinuation will be recorded on a specific form. The schedule of enrollment, interventions, and assessments is reported in Table 1.

Sample Size
The calculation of the sample power is based on literature data (25, 36–40) to obtain 25% of improvement in the primary endpoint using G*Power 3.1.9.7 (41). The formula for calculating the sample size is given, for two arms of the same size, as it follows:

\[ n = \frac{\left(\frac{Z_{\alpha/2} + Z_{\beta}}{Z_{0.84}}\right)^2 \times \left(2\sigma^2\right)}{(\mu_1 - \mu_2)^2} \]

where,
- \( n \) = sample size required in each group;
- \( Z_{\alpha/2} = 1.96 \), according to 5% level of significance;
- \( Z_{\beta} = 0.84 \) for 80% power;
- \( \sigma \) = standard deviation;
- \( \mu_1 - \mu_2 \) = primary outcome measures significant difference = 6.34 with ARAMIS and 5.4 with conventional rehabilitation (25); \( d = 0.3 \).

Therefore, considering a 95% confidence level and a study power of 80% (42), the result will be \( n = 53 \) per arm.

Adjusted sample size \( n_1 \) to account for potential drop-out rates is \( n_1 = n/\left(1 - d\right) \), where \( d = 10\% \) (43), thus \( n_1 = 118 \) patients will be recruited, 59 per each arm.

Recruitment, Allocation, Concealment, and Blinding
The recruitment will occur at the study setting (Sant’ Anna Institute) to reach the target sample size. Patients will be randomly allocated to in a 1:1 allocation ratio to ARAMIS or conventional neurorehabilitation group. Different researchers/operators will independently recruit patients, generate the allocation sequence, and assign participants to interventions and no member of the trial will have access to the codes up to the end. Both males and females will be enrolled due to differences in baseline pain perception (44) and to sex-treatment interactions (45). Therefore, no blocking will occur but minimization will be performed for sex-difference in pain perception, handled to ensure that any individual who might introduce bias is not involved (46). The codes of allocation will be generated using Random Number selection Microsoft Office Excel 2010 (Microsoft, Milan, Italy). Blinding of data managers and biostatisticians after assignment to interventions and also about the nature of the interventions will be ensured (47). Accordingly, who will be in charge of preparing the randomization list will be someone other than the data managers and biostatisticians (47). The allocation will never be revealed up to the end of the trial. Double data entry will be performed by two independent operators for security and data quality. To guarantee the protection of confidentiality, only the responsible secretariat of the clinical center will collect and maintain the personal information of patients. Not having a trial sponsor, auditing will be independent.

Statistical Analysis
The statistical analysis plan follows the Consolidated Standards of Reporting Trials (CONSORT) evidence-based reporting guideline to ensure research transparency, specifically to trials of nonpharmacologic treatments (NPTs), as rehabilitation (48). The primary (pain) and secondary (spasticity and rehabilitation parameters) outcome measures, collected at prespecified time point t₁ and t₄ vs. t₀, will be expressed as mean and standard error and assessed for statistically significant differences using independent t-test for data normally distributed or Mann–Whitney U test for skewed data. Based on the CONSORT NPT item 12b, the evaluation of the outcome measures over time will be carried out through a linear mixed model. The correlation between pain (VAS measure) and recovery (FMA-UE), assessed at t₀, t₁, t₂, t₃, and t₄, will be performed through the Pearson product-moment correlation coefficient (r). In agreement with the CONSORT NPT item 12a, the clustering of data will be performed by blinded care providers of the center. Statistical analysis will be performed using SPSS statistics software (Chicago, IL, USA). Values of \( p < 0.05 \) will be considered statistically significant.

DISCUSSION
Cerebrovascular accidents are often accompanied by motor disability and chronic pain. Poststroke pain consists of complex syndromes including both nociceptive musculoskeletal and
neuropathic features (49). Due to its characteristics, poststroke pain is often underdiagnosed and unrelieved (50). The best management option for chronic pain consists of its prevention. To this aim, this is the first clinical trial to study the use of an IRSS in subacute neurorehabilitation after stroke. In particular, ARAMIS has provided more efficacy than conventional poststroke neurorehabilitation when applied for 7–8 weeks in the improvement of motor function and activities of daily living (17, 25, 51, 52). When the lesion is high after lateral medullary infarction, known as Wallenberg’s syndrome, or in the ventroposterior part of the thalamus, central poststroke pain ensues (6). In the event hemiparesis occurs, the healthy arm may offset the effect of spasticity and locomotion (52, 53). Within this frame, ARAMIS may prevent central pain, and, concurrently, may drive correct re-organization in hemiplegic patients capturing the motions and the strength of the unaffected upper limb. In fact, ARAMIS consists of two exoskeletons with 6 degrees of freedom driven by two engines and controlling the shoulder joints to compensate for the inadequate motility and strength of the paretic arm (51). Robot-assisted motor rehabilitation and myoelectrical stimulation are demonstrated to provide reduction of the upper limb impairment (38, 39, 54–56) and pain improvement (40, 57, 58). Also, actigraphic measure systems can predict acute phase stroke prognosis (59), supporting the role of technological progress in stroke. Furthermore, the use of these devices can help the familiarization of poststroke survivors with the latter technology (60). However, a decrease in upper limb impairment does not always correlate to practical and daily functional improvement and this translational aspect needs to be studied for effective neurorehabilitation (61). In fact, the wide multicenter trial for the evaluation of robot-assisted training for the upper limb after stroke (RATULS) has demonstrated that robotic neurorehabilitation does not significantly improve the upper limb function (62). Pain intensity has been positively correlated with time since stroke and negatively with motor function (44), supporting the need to examine the role of robot-assisted rehabilitation in pain processing and to clear the mechanisms necessary for effective functional gain. The latter is a top ten priority for stroke survivors (63). Therefore, the role of ARAMIS-assisted neurorehabilitation in the prevention of poststroke pain occurring 3–6 months after stroke deserves investigation. The efficacy of robot-assisted neurorehabilitation in the prevention of chronic poststroke pain could pose the basis for a remarkable improvement of stroke sufferers’ quality of life. Moreover, a better and deeper understanding of robot-related motor learning is needed (55) and, although the stage is a predictor for better rehabilitation outcomes, IRSS neurorehabilitation, without significant differences among the several devices existing (64), has proven promising results also in chronic stroke survivors (65). In this already fragile population, robot-assisted rehabilitation may also reduce the use of analgesics known to be endowed with serious side effects. In fact, fragile populations are often subjected to limited and inappropriate pain treatment (66–68). The next step will consist in investigating the effect of this neurorehabilitation procedure on the use of analgesics, both synthetic and of natural origin, as the essential oil of bergamot endowed with analgesic (69) and flumazenil insensitive anxiolytic-like (70) properties and which has been engineered allowing double-blind clinical trials (71, 72).

**REFERENCES**

1. Krishnamurthi RV, Ikeda T, Feigin VL. Global, regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the global burden of disease study 2017. *Neuropedemiology.* (2020) 54:171–9. doi: 10.1159/000506396
2. Luke C, Dodd KL, Brock K. Outcomes of the Bobath concept on upper limb recovery following stroke. *Clin Rehabil.* (2004) 18:888–98. doi: 10.1191/0269215504cr793oa
3. Urton ML, Kohia M, Davis J, Neill MR. Systematic literature review of treatment interventions for upper extremity hemiparesis following stroke. *Occup Ther Int.* (2007) 14:11–27. doi: 10.1002/oti.220
4. Merskey H, Bogduk N. Task force on taxonomy of the international association for the study of pain. Classification of chronic pain: descriptions of chronic pain syndromes and definition of pain terms. *Pain.* (1994) 2:209–14.
5. Paolucci S, Isola M, Toni D, Barbanti P, Bovi P, Cavallini A, et al. Prevalence and time course of post-stroke pain: a multicenter prospective hospital-based study. *Pain Med (Malden, Mass).* (2016) 17:924–30. doi: 10.1093/pm/pnv019
6. Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. *Lancet Neurol.* (2009) 8:857–68. doi: 10.1016/S1474-4422(09)70176-0
7. Hansen AP, Marcussen NS, Klit H, Kasch H, Jensen TS, Finnerup NB. Development of persistent headache following stroke: a 3-year follow-up. *Cephalalgia.* (2015) 35:399–409. doi: 10.1177/0333102415458984
8. O’Donnell MJ, Diener HC, Sacco RL, Panju AA, Vinisko R, Yusuf S. Chronic pain syndromes after ischemic stroke: PRoFESS trial. *Stroke.* (2013) 44:1238–43. doi: 10.1161/STROKEAHA.111.671088
9. Kim JS. Pharmacological management of central post-stroke pain: a practical guide. *CNS Drugs.* (2014) 28:787–97. doi: 10.1007/s40263-014-0194-y
10. Lundström E, Smits A, Terënt A, Borg J. Risk factors for stroke-related pain 1 year after first-ever stroke. *Eur J Neurol.* (2009) 16:188–93. doi: 10.1111/j.1468-1331.2008.02378.x
11. Scuteri D, Mantovani E, Tamburin S, Sandrini G, Corasaniti MT, Bagetta G, et al. Opioids in post-stroke pain: a systematic review and meta-analysis. *Front Pharmacol.* (2020) 11:587050. doi: 10.3389/fphar.2020.587050
12. Scuteri D, Corasaniti MT, Tonin P, Bagetta G. Eptinezumab for the treatment of migraine. *Drugs Today.* (2019) 55:695–703. doi: 10.1358/dot.2019.55.11.3069864
13. de Vries NJ, Sloot PH. Achterberg WP. Pain and pain assessment in stroke patients with aphasia: a systematic review. *Aphasiology.* (2017) 31:703–19. doi: 10.1080/02687038.2016.1254150
14. Scuteri D, Rombolá L, Morrone LA, Bagetta G, Sakurada S, Sakurada T, et al. Neuropharmacology of the neuropsychiatric symptoms of dementia and role...
of pain: essential oil of bergamot as a novel therapeutic approach. Int J Mol Sci. (2019) 20:3327. doi: 10.3390/ijms20133327

15. Scuteri D, Rombolà L, Tridico L, Mizoguchi H, Watanabe C, Sakurada T, et al. Neuropharmacological properties of the essential oil of bergamot for the clinical management of pain-related BPSDs. Curr Med Chem. (2019) 26:7364–74. doi: 10.2174/0929867166666180307115546

16. Scuteri D, Matamala-Gomez M, Bottiri S, Corasaniti MT, De Icco R, Baggetta G, et al. Pain assessment and treatment in dementia at the time of coronavirus disease COVID-19. Front Neurol. (2020) 11:890. doi: 10.3389/fneur.2020.00890

17. Pignolo L, Serra S, Basta G, Carozzo S, Arcuri F, Pignataro LM, et al. On a new neurorehabilitation approach targeting functional recovery in stroke patients. Data in brief. (2019) 27:104685. doi: 10.1016/j.dib.2019.104685

18. Ballester BR, Maier M, San Segundo Mozo RM, Castañeda V, Duff AMJ, Verschure PF. Counteracting learned non-use in chronic stroke patients with reinforcement-induced movement therapy. J Neurorehabil. (2016) 13:74. doi: 10.1186/s12984-016-0178-x

19. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Consensus-based core set of outcome measures for clinical trials. Pain. (2003) 106:337–45. doi: 10.1016/j.pain.2003.08.001

20. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, KrleŽa-Jeri ´c K, et al. SPIRIT: a statement of preferred reporting items for clinical trials—extension to nonpharmacologic trial abstracts. Ann Intern Med. (2013) 158:200–7. doi: 10.7326/0003-4819-158-3-201302050-00583

21. Gladstone DJ, Dancl J, Armeto A, McIroy WE, Staines WR, Graham SJ, et al. Physiotherapy coupled with dextroamphetamine as rehabilitation after hemiparetic stroke. Stroke. (2006) 37:179–85. doi: 10.1161/01.STR.0000195169.42477.8

22. Benaim C, Waquoix G, Pérennou D, Pisicelli C, Lucas-Pinea u B, Bonnin-Koang H-Y, et al. Connectivity measures are robust biomarkers of cortical function and validity. J Neuroimaging. (2014) 24:1290–9. doi: 10.1111/jen.13577

23. Aprile I, Germanotta M, Cruciani A, Pecchioli C, Loreti S, Papadopoulos D, Treasure T, MacRae KD. Minimisation: the platinum standard for trials? J Psychiatr Res. (2010) 44:1011–6. doi: 10.1016/j.jpsychires.2009.10.004

24. Hansson P. Post-stroke pain case study: clinical characteristics, therapeutic options and long-term follow-up. Eur J Neurol. (2008) 15:240–9. doi: 10.1111/j.1468-1331.2008.02179.x

25. Pignolo L, Serra S, Basta G, Carozzo S, Arcuri F, Pignataro LM, et al. Connectivity measures are robust biomarkers of cortical function and validity. J Neuroimaging. (2014) 24:1290–9. doi: 10.1111/jen.13577

26. Kim MS, Kim SH, Noh SE, Bang HJ, Lee KM. Robotic-assisted shoulder rehabilitation therapy effectively improved poststroke hemiplegic shoulder pain: a randomized controlled trial. Arch Phys Med Rehabil. (2010) 91:1015–22. doi: 10.1016/j.apmr.2009.02.003

27. Thorsen R, Cortesi M, Jonsdottir J, Carpinella I, Morelli D, Casiraghi A, et al. Myoelectrically driven functional electrical stimulation may increase motor recovery of upper limb in poststroke subjects: a randomized controlled pilot study. J Rehabil Res Dev. (2013) 50:785–94. doi: 10.1682/JRRD.2012.07.0123

28. Platz T, Vuadens P, Eickhof C, Arnold P, Van Kaick S, Heise K, et al. A summary of pain: essential oil of bergamot as a novel therapeutic approach. Int J Mol Sci. (2019) 20:3327. doi: 10.3390/ijms20133326.36847.b0
53. Ustinova KI, Goussev VM, Balasubramaniam R, Leven MF. Disruption of coordination between arm, trunk, and center of pressure displacement in patients with hemiparesis. Motor Control. (2004) 8:139–59. doi: 10.1123/mc.8.2.139
54. Jonsdottir J, Thorsen R, Aprile I, Galeri S, Spannocchi G, Beghi E, et al. Arm rehabilitation in post stroke subjects: A randomized controlled trial on the efficacy of myoelectrically driven FES applied in a task-oriented approach. PLoS ONE. (2017) 12:e0188642. doi: 10.1371/journal.pone.0188642
55. Veerbeek JM, Langbroek-Amersfoort AC, van Wegen EE, Meskers CG, Kwakkel G. Effects of Robot-Assisted Therapy for the Upper Limb After Stroke. Neurorehabil Neural Repair. (2017) 31:107–21. doi: 10.1177/1558944716666957
56. Budhota A, Chua KSG, Hussain A, Kager S, Cherpin A, Contu S, et al. Robotic assisted upper limb training post stroke: a randomized controlled trial using combinatory approach toward reducing workforce demands. Front Neurol. (2021) 12:622014. doi: 10.3389/fneur.2021.622014
57. Villafañe JH, Taveggia G, Galeri S, Bissolotti L, Mullè C, Imperio G, et al. Efficacy of short-term robot-assisted rehabilitation in patients with hand paralysis after stroke: a randomized clinical trial. Hand (New York). (2018) 13:95–102. doi: 10.1177/1558944717692096
58. Serreuzella RR, Quezada MT, Zayas MH, Pedrón AM, Hermosilla DM, Zamora RS. Robotic therapy for the hemiplegic shoulder pain: a pilot study. J Neuroeng Rehabil. (2020) 17:54. doi: 10.1186/s12984-020-00674-6
59. Reale G, Giovannini S, Iacovelli C, Castiglia SF, Picerno P, Zaudi A, et al. Actigraphic measurement of the upper limbs for the prediction of ischemic stroke prognosis: an observational study. Sensors (Basel). (2021) 21:2479. doi: 10.3390/s21072479
60. Ranzani R, Lambarcy O, Metzger J-C, Thoren R, Aprile I, Galeri S, Spannocchi G, Beghi E, et al. Arm rehabilitation in post stroke subjects: A randomized controlled trial on the efficacy of myoelectrically driven FES applied in a task-oriented approach. PLoS ONE. (2017) 12:e0188642. doi: 10.1371/journal.pone.0188642
61. Rodgers H, Bosomworth H, Krebs HI, van Wijck F, Howel D, Wilson N, et al. Robot-assisted training compared with an enhanced upper limb therapy programme and with usual care for upper limb functional limitation after stroke: the RATULS three-group RCT. Health Technol Assess (Winchester, England). (2020) 24:1–232. doi: 10.3310/hta24540
62. Rodgers H, Bosomworth H, Krebs HI, van Wijck F, Howel D, Wilson N, et al. Robot-assisted training for the upper limb after stroke. (RATULS): a multicentre randomised controlled trial. Lancet (London, England). (2019) 394:51–62. doi: 10.1016/S0140-6736(19)31055-4
63. Pollock A, St George B, Fenton M, Finkins L. Top 10 research priorities relating to life after stroke—consensus from stroke survivors, caregivers, and health professionals. Int J Stroke. (2014) 9:313–20. doi: 10.1111/1747-4949.2012.00942.x
64. Mehrholz J, Pollock A, Pohl M, Kugler J, Elnsner B. Systematic review with network meta-analysis of randomized controlled trials of robotic-assisted arm training for improving activities of daily living and upper limb function after stroke. J Neuroeng Rehabil. (2020) 17:83. doi: 10.1186/s12984-020-00715-0
65. Bertani R, Melegari C, De Cola MC, Bramanti A, Bramanti P, Calabró RS. Effects of robot-assisted upper limb rehabilitation in stroke patients: a systematic review with meta-analysis. Neurol Sci. (2017) 38:1561–9. doi: 10.1007/s10072-017-2995-5
66. Scuteri D, Vulnera M, Piro B, Bossio RB, Morrone LA, Sandrini G, et al. Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia. Eur J Clin Pharmacol. (2021) 77:241–9. doi: 10.1007/s00228-020-02995-w
67. Scuteri D, Garreffa MR, Esposito S, Bagetta G, Naturale MD, Corasaniti MT. Evidence for accuracy of pain assessment and painkillers utilization in neuropsychiatric symptoms of dementia in Calabria region, Italy. Neural Regener Res. (2018) 13:1619–21. doi: 10.4103/1673-5374.237125
68. Scuteri D, Piro B, Morrone LA, Corasaniti MT, Vulnera M, Bagetta G. The need for better access to pain treatment: learning from drug consumption trends in the USA. Funct Neurol. (2017) 22:229–30. doi: 10.1123/fneur.2017.32.4.229
69. Scuteri D, Crudo M, Rombolà L, Watanabe C, Mizoguchi H, Sakurada S, et al. Antinociceptive effect of inhalation of the essential oil of bergamot in mice. Fitoterapia. (2018) 129:20–4. doi: 10.1016/j.fitote.2018.06.007
70. Rombolà L, Scuteri D, Adornetto A, Straface M, Sakurada T, Sakurada S, et al. Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats. Evid Based Complement Alternat Med. (2019) 2019:2156873. doi: 10.1155/2019/2156873
71. Scuteri D, Cassano R, Trombino S, Russo R, Mizoguchi H, Watanabe C, et al. Development and Translation of NanoBEO, a Nanotechnology-Based Delivery System of Bergamot Essential Oil Deprived of Furocoumarins, in the Control of Agitation in Severe Dementia. Pharmaceutics. (2021) 13:379. doi: 10.3390/pharmaceutics13030379
72. Scuteri D, Sandrini G, Tamburin S, Corasaniti MT, Nicotera P, Tonin P, et al. Bergamot rehabilitation AgaINst agitation in dementia. (BRAIN AID): study protocol for a randomized, double-blind, placebo-controlled trial to assess the efficacy of furocoumarin-free bergamot loaded in a nanotechnology-based delivery system of the essential oil in the treatment of agitation in elderly affected by severe dementia. Phytother Res. (2021) 35:533–8. doi: 10.1002/tr.7223

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pignolo, Tonin, Nicotera, Bagetta and Scuteri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.